Cargando…
Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies
BACKGROUND: Individualized neoantigen-specific immunotherapy (iNeST) requires robustly expressed clonal neoantigens for efficacy, but tumor mutational heterogeneity, loss of neoantigen expression, and variable tissue sampling present challenges. It is assumed that clonal neoantigens are preferred ta...
Autores principales: | Lo, Amy A, Wallace, Andrew, Oreper, Daniel, Lounsbury, Nicolas, Havnar, Charles, Pechuan-Jorge, Ximo, Wu, Thomas D, Bourgon, Richard, Jones, Ryan, Krogh, Katrina, Yang, Guang-Yu, Zill, Oliver A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488717/ https://www.ncbi.nlm.nih.gov/pubmed/34599029 http://dx.doi.org/10.1136/jitc-2021-003001 |
Ejemplares similares
-
Origins and Timing of Emerging Lesions in Advanced Renal Cell Carcinoma
por: Wallace, Andrew, et al.
Publicado: (2022) -
Neoantigens as potential vaccines in hepatocellular carcinoma
por: Repáraz, David, et al.
Publicado: (2022) -
Protein citrullination as a source of cancer neoantigens
por: Katayama, Hiroyuki, et al.
Publicado: (2021) -
T cells of colorectal cancer patients’ stimulated by neoantigenic and cryptic peptides better recognize autologous tumor cells
por: Schwarz, Sandra, et al.
Publicado: (2022) -
Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion
por: D'Alise, Anna Morena, et al.
Publicado: (2021)